Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
Merck
Medtronic
McKinsey

Last Updated: December 3, 2022

Details for Patent: 8,574,626


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,574,626 protect, and when does it expire?

Patent 8,574,626 protects OSMOLEX ER and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,574,626
Title:Osmotic device containing amantadine and an osmotic salt
Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.
Inventor(s): Vergez; Juan A. (Buenos Aires, AR), Faour; Joaquina (Buenos Aires, AR), Pastini; Ana C. (Buenos Aires, AR), Bigatti; Guido S. (Buenos Aires, AR), Meyer; Glenn A. (Wilmington, NC), Feleder; Ethel C. (Buenos Aires, AR), Ricci; Marcelo A. (Buenos Aires, AR), Coppari; Marcelo A. (Buenos Aires, AR), Befumo; Marcelo F. (Buenos Aires, AR)
Assignee: Osmotica Kereskedelmi es Szolgaltato KFT (Budapest, HU)
Application Number:13/551,755
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,574,626
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Device;

Drugs Protected by US Patent 8,574,626

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Adamas Operations OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-001 Feb 16, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT See Plans and Pricing
Adamas Operations OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-004 Apr 22, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT See Plans and Pricing
Adamas Operations OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-002 Feb 16, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT See Plans and Pricing
Adamas Operations OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-003 Feb 16, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,574,626

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 053986 See Plans and Pricing
Australia 2005328058 See Plans and Pricing
Brazil PI0515761 See Plans and Pricing
Canada 2589479 See Plans and Pricing
European Patent Office 1834638 See Plans and Pricing
European Patent Office 2965753 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Colorcon
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.